Literature DB >> 16398644

Stable peptide inhibitors prevent binding of lethal and oedema factors to protective antigen and neutralize anthrax toxin in vivo.

Alessandro Pini1, Ylenia Runci, Chiara Falciani, Barbara Lelli, Jlenia Brunetti, Silvia Pileri, Monica Fabbrini, Luisa Lozzi, Claudia Ricci, Andrea Bernini, Fiorella Tonello, Federica Dal Molin, Paolo Neri, Neri Niccolai, Luisa Bracci.   

Abstract

The lethal and oedema toxins produced by Bacillus anthracis, the aetiological agent of anthrax, are made by association of protective antigen with lethal and oedema factors and play a major role in the pathogenesis of anthrax. In the present paper, we describe the production of peptide-based specific inhibitors in branched form which inhibit the interaction of protective antigen with lethal and oedema factors and neutralize anthrax toxins in vitro and in vivo. Anti-protective antigen peptides were selected from a phage library by competitive panning with lethal factor. Selected 12-mer peptides were synthesized in tetra-branched form and were systematically modified to obtain peptides with higher affinity and inhibitory efficiency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16398644      PMCID: PMC1409687          DOI: 10.1042/BJ20051747

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  18 in total

1.  Designing a polyvalent inhibitor of anthrax toxin.

Authors:  M Mourez; R S Kane; J Mogridge; S Metallo; P Deschatelets; B R Sellman; G M Whitesides; R J Collier
Journal:  Nat Biotechnol       Date:  2001-10       Impact factor: 54.908

2.  Identification of amino acid residues of anthrax protective antigen involved in binding with lethal factor.

Authors:  Vibha Chauhan; Rakesh Bhatnagar
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

3.  Rational design and molecular diversity for the construction of anti-alpha-bungarotoxin antidotes with high affinity and in vivo efficiency.

Authors:  Luisa Lozzi; Barbara Lelli; Ylenia Runci; Silvia Scali; Andrea Bernini; Chiara Falciani; Alessandro Pini; Neri Niccolai; Paolo Neri; Luisa Bracci
Journal:  Chem Biol       Date:  2003-05

Review 4.  Antitoxins: novel strategies to target agents of bioterrorism.

Authors:  G Jonah A Rainey; John A T Young
Journal:  Nat Rev Microbiol       Date:  2004-09       Impact factor: 60.633

5.  Synthetic peptides in the form of dendrimers become resistant to protease activity.

Authors:  Luisa Bracci; Chiara Falciani; Barbara Lelli; Luisa Lozzi; Ylenia Runci; Alessandro Pini; Maria Graziella De Montis; Alessandro Tagliamonte; Paolo Neri
Journal:  J Biol Chem       Date:  2003-09-12       Impact factor: 5.157

6.  Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor.

Authors:  G Vitale; L Bernardi; G Napolitani; M Mock; C Montecucco
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

7.  Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system.

Authors:  J P Tam
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

8.  Identification of the cellular receptor for anthrax toxin.

Authors:  K A Bradley; J Mogridge; M Mourez; R J Collier; J A Young
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

9.  Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.

Authors:  S H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

Review 10.  Anthrax toxin rafts into cells.

Authors:  Teymuras Kurzchalia
Journal:  J Cell Biol       Date:  2003-02-03       Impact factor: 10.539

View more
  9 in total

1.  Peptide inhibitors MAP the way towards fighting anthrax pathogenesis.

Authors:  Aimee M DeCathelineau; Gary M Bokoch
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

2.  A serum-stable branched dimeric anti-VEGF peptide blocks tumor growth via anti-angiogenic activity.

Authors:  Jung-Wook Kim; Tae-Dong Kim; Bok Sil Hong; Oh Youn Kim; Wan-Hee Yoon; Chi-Bom Chae; Yong Song Gho
Journal:  Exp Mol Med       Date:  2010-07-31       Impact factor: 8.718

3.  Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening.

Authors:  Ludovic Bannwarth; Allison B Goldberg; Catherine Chen; Benjamin E Turk
Journal:  Chem Biol       Date:  2012-07-27

4.  A dual-purpose protein ligand for effective therapy and sensitive diagnosis of anthrax.

Authors:  Momchilo Vuyisich; S Gnanakaran; Julie A Lovchik; C Rick Lyons; Goutam Gupta
Journal:  Protein J       Date:  2008-08       Impact factor: 2.371

Review 5.  Inhibitors of the Metalloproteinase Anthrax Lethal Factor.

Authors:  Allison B Goldberg; Benjamin E Turk
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

6.  Isomerization of an antimicrobial peptide broadens antimicrobial spectrum to gram-positive bacterial pathogens.

Authors:  Chiara Falciani; Luisa Lozzi; Simona Pollini; Vincenzo Luca; Veronica Carnicelli; Jlenia Brunetti; Barbara Lelli; Stefano Bindi; Silvia Scali; Antonio Di Giulio; Gian Maria Rossolini; Maria Luisa Mangoni; Luisa Bracci; Alessandro Pini
Journal:  PLoS One       Date:  2012-10-02       Impact factor: 3.240

Review 7.  Display technologies: application for the discovery of drug and gene delivery agents.

Authors:  Anna Sergeeva; Mikhail G Kolonin; Jeffrey J Molldrem; Renata Pasqualini; Wadih Arap
Journal:  Adv Drug Deliv Rev       Date:  2006-10-06       Impact factor: 15.470

Review 8.  Bacillus anthracis edema factor substrate specificity: evidence for new modes of action.

Authors:  Martin Göttle; Stefan Dove; Roland Seifert
Journal:  Toxins (Basel)       Date:  2012-07-06       Impact factor: 4.546

Review 9.  Bacillus anthracis: balancing innocent research with dual-use potential.

Authors:  Michael J Hudson; Wolfgang Beyer; Reinhard Böhm; Antonio Fasanella; Giuliano Garofolo; Robert Golinski; Pierre L Goossens; Ulrike Hahn; Bassam Hallis; Annemarie King; Michèle Mock; Cesare Montecucco; Amanda Ozin; Fiorella Tonello; Stefan H E Kaufmann
Journal:  Int J Med Microbiol       Date:  2008-03-28       Impact factor: 3.473

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.